All In Biotech

Drug Trial Radar · NCT05545111

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Oct 4, 2022

Primary completion

Jul 10, 2024

Study completion Jul 10, 2024

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Sep 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.

Conditions

  • Schizophrenia

Interventions

  • NBI-1117568Drug

    Active treatment with orally administered NBI-1117568

  • PlaceboDrug

    Placebo matching NBI-1117568

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6Time frame: Baseline and Week 6

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Little Rock, Arkansas

  • Neurocrine Clinical Site

    Rogers, Arkansas

  • Neurocrine Clinical Site

    Lemon Grove, California

  • Neurocrine Clinical Site

    Pico Rivera, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    Torrance, California

  • Neurocrine Clinical Site

    Miami Lakes, Florida

  • Neurocrine Clinical Site

    Oakland Park, Florida

  • Neurocrine Clinical Site

    Gaithersburg, Maryland

  • Neurocrine Clinical site

    St Louis, Missouri

  • Neurocrine Clinical Site

    Berlin, New Jersey

  • Neurocrine Clinical Site

    North Canton, Ohio

  • Neurocrine Clinical Site

    Austin, Texas

  • Neurocrine Clinical Site

    DeSoto, Texas

  • Neurocrine Clinical Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.